Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Surveying the global virome: Identification and characterization of HCV-related animal hepaciviruses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inhibition of HIV-1 in vitro by C-5 propyne phosphorothioate antisense to rev.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  3. Effect of anti-carbohydrate antibodies on HIV infection in a monocytic cell line (U937).

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • A Horvath
  • I Andersen
  • K Junker
  • B Lyck Fogh-Schultz
  • E Holm Nielsen
  • S Gizurarson
  • Ove Andersen
  • J Karman
  • E Rajnavolgyi
  • A Erdei
  • SE Svehag
Vis graf over relationer
Serum amyloid P component (SAP) binds in vitro Ca(2+)-dependently to several ligands including oligosaccharides with terminal mannose and galactose. We have earlier reported that SAP binds to human influenza A virus strains, inhibiting hemagglutinin (HA) activity and virus infectivity in vitro. These studies were extended to comprise five mouse-adapted influenza A strains, two swine influenza A strains, a mink influenza A virus, a ferret influenza A reassortant virus, a influenza B virus and a parainfluenza 3 virus. The HA activity of all these viruses was inhibited by SAP. Western blotting showed that SAP bound to HA trimers, monomers and HA1 and HA2 subunits of influenza A virus. Binding studies indicated that galactose, mannose and fucose moieties contributed to the SAP reacting site(s). Intranasal administration of human SAP to mice induced no demonstrable toxic reactions, and circulating antibodies against SAP were not detected. Preincubation of virus (A/Japan/57) with SAP prevented primary infection of mice and development of antiviral antibodies. After a single intranasal administration of SAP (40 microg) 1 h before primary infection with virus (2LD(50)), nine out of 10 mice survived on day 10 and these mice approached normal body weight, whereas control mice (one out of five surviving on day 10) died. The data provide evidence of the potential of intranasally administered SAP for prophylactic treatment of influenza A virus infections in humans.
OriginalsprogEngelsk
TidsskriftAntiviral Research
Vol/bind52
Udgave nummer1
Sider (fra-til)43-53
ISSN0166-3542
DOI
StatusUdgivet - 2001

ID: 32578726